Association Between Platelet Glycoprotein IIb/IIIa Inhibition and In-Hospital Outcomes in ST-Elevation Myocardial Infarction Patients Treated with Coronary Thrombus Aspiration : Findings from the CCC-ACS Project
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature..
PURPOSE: Thrombus aspiration in ST-elevation myocardial infarction (STEMI) with high thrombus burden did not improve clinical outcomes. The clinical efficacy of the bailout use of platelet glycoprotein IIb/IIIa inhibitors (GPIs) in this clinical scenario remains unknown.
METHODS: We assessed associations between GPI use and in-hospital major bleeds, ischemic events, and mortality among STEMI patients treated with percutaneous coronary intervention (PCI) and thrombus aspiration in a nationwide acute coronary syndrome registry (the Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome project).
RESULTS: A total of 5896 STEMI patients who received thrombus aspiration were identified, among which 56.3% received GPI therapy. In a 1-to-1 propensity-score-matched cohort, compared with STEMI patients not treated with GPI, GPI use was associated with a 69% increase in major in-hospital bleeds, with an odds ratio (OR) of 1.69, a 95% confidence interval (CI) of 1.08 to 2.65, and a nonsignificant reduction in ischemic events (OR: 0.61, 95% CI: 0.36 to 1.06), as well as a neutral effect on mortality (OR: 0.93, 95% CI: 0.55 to 1.58). However, among patients aged < 60 years, GPI use was associated with a reduction in ischemic events (OR: 0.27, 95% CI: 0.08 to 0.98), and no significant increase in major bleeds was observed.
CONCLUSION: In a nationwide registry, routine use of GPI following thrombus aspiration was not associated with reduced in-hospital ischemic events and mortality but at the cost of increased major bleeding. However, for patients aged < 60 years, there may be a potential net benefit.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Cardiovascular drugs and therapy - 38(2024), 2 vom: 04. März, Seite 315-325 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Wennan [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 25.03.2024 Date Revised 25.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10557-022-07398-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348564066 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348564066 | ||
| 003 | DE-627 | ||
| 005 | 20240325234127.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10557-022-07398-w |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1346.xml |
| 035 | |a (DE-627)NLM348564066 | ||
| 035 | |a (NLM)36342561 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Wennan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Association Between Platelet Glycoprotein IIb/IIIa Inhibition and In-Hospital Outcomes in ST-Elevation Myocardial Infarction Patients Treated with Coronary Thrombus Aspiration |b Findings from the CCC-ACS Project |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.03.2024 | ||
| 500 | |a Date Revised 25.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. | ||
| 520 | |a PURPOSE: Thrombus aspiration in ST-elevation myocardial infarction (STEMI) with high thrombus burden did not improve clinical outcomes. The clinical efficacy of the bailout use of platelet glycoprotein IIb/IIIa inhibitors (GPIs) in this clinical scenario remains unknown | ||
| 520 | |a METHODS: We assessed associations between GPI use and in-hospital major bleeds, ischemic events, and mortality among STEMI patients treated with percutaneous coronary intervention (PCI) and thrombus aspiration in a nationwide acute coronary syndrome registry (the Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome project) | ||
| 520 | |a RESULTS: A total of 5896 STEMI patients who received thrombus aspiration were identified, among which 56.3% received GPI therapy. In a 1-to-1 propensity-score-matched cohort, compared with STEMI patients not treated with GPI, GPI use was associated with a 69% increase in major in-hospital bleeds, with an odds ratio (OR) of 1.69, a 95% confidence interval (CI) of 1.08 to 2.65, and a nonsignificant reduction in ischemic events (OR: 0.61, 95% CI: 0.36 to 1.06), as well as a neutral effect on mortality (OR: 0.93, 95% CI: 0.55 to 1.58). However, among patients aged < 60 years, GPI use was associated with a reduction in ischemic events (OR: 0.27, 95% CI: 0.08 to 0.98), and no significant increase in major bleeds was observed | ||
| 520 | |a CONCLUSION: In a nationwide registry, routine use of GPI following thrombus aspiration was not associated with reduced in-hospital ischemic events and mortality but at the cost of increased major bleeding. However, for patients aged < 60 years, there may be a potential net benefit | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Bleeding | |
| 650 | 4 | |a Percutaneous coronary intervention | |
| 650 | 4 | |a Platelet glycoprotein IIb/IIIa inhibitors | |
| 650 | 4 | |a ST-elevation myocardial infarction | |
| 650 | 7 | |a Platelet Aggregation Inhibitors |2 NLM | |
| 650 | 7 | |a Platelet Glycoprotein GPIIb-IIIa Complex |2 NLM | |
| 650 | 7 | |a Platelet Membrane Glycoproteins |2 NLM | |
| 700 | 1 | |a Li, Ziping |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Tianqi |e verfasserin |4 aut | |
| 700 | 1 | |a A, Geru |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Haonan |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Hangkuan |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Xiwen |e verfasserin |4 aut | |
| 700 | 1 | |a Jin, Zhengyang |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Linjie |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yongle |e verfasserin |4 aut | |
| 700 | 1 | |a Hao, Yongchen |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Dong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Qing |e verfasserin |4 aut | |
| 700 | 0 | |a CCC-ACS investigators |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Aihua |e investigator |4 oth | |
| 700 | 1 | |a Li, Bao |e investigator |4 oth | |
| 700 | 1 | |a Xu, Biao |e investigator |4 oth | |
| 700 | 1 | |a Han, Guangshu |e investigator |4 oth | |
| 700 | 1 | |a Li, Bin |e investigator |4 oth | |
| 700 | 1 | |a Liu, Bin |e investigator |4 oth | |
| 700 | 1 | |a Wang, Bin |e investigator |4 oth | |
| 700 | 1 | |a Fu, Bing |e investigator |4 oth | |
| 700 | 1 | |a Yu, Bo |e investigator |4 oth | |
| 700 | 1 | |a Yang, Bosong |e investigator |4 oth | |
| 700 | 1 | |a Luo, Caidong |e investigator |4 oth | |
| 700 | 1 | |a Wang, Changqian |e investigator |4 oth | |
| 700 | 1 | |a Liu, Changyong |e investigator |4 oth | |
| 700 | 1 | |a Liang, Chuanliang |e investigator |4 oth | |
| 700 | 1 | |a Gao, Chuanyu |e investigator |4 oth | |
| 700 | 1 | |a Lai, Chunlin |e investigator |4 oth | |
| 700 | 1 | |a Wang, Chuntong |e investigator |4 oth | |
| 700 | 1 | |a Zhang, Chunyan |e investigator |4 oth | |
| 700 | 1 | |a Wu, Chunyang |e investigator |4 oth | |
| 700 | 1 | |a Zhang, Congliang |e investigator |4 oth | |
| 700 | 1 | |a Bin, Cui |e investigator |4 oth | |
| 700 | 1 | |a Huang, Lan |e investigator |4 oth | |
| 700 | 1 | |a Peng, Daoquan |e investigator |4 oth | |
| 700 | 1 | |a Xu, Dawen |e investigator |4 oth | |
| 700 | 1 | |a Wu, Di |e investigator |4 oth | |
| 700 | 1 | |a Zhu, Dongmei |e investigator |4 oth | |
| 700 | 1 | |a Chai, Dongsheng |e investigator |4 oth | |
| 700 | 1 | |a Li, Dongyan |e investigator |4 oth | |
| 700 | 1 | |a Tang, Fakuan |e investigator |4 oth | |
| 700 | 1 | |a Xiao, Jun |e investigator |4 oth | |
| 700 | 1 | |a Zhao, Fang |e investigator |4 oth | |
| 700 | 1 | |a Huang, Fangfang |e investigator |4 oth | |
| 700 | 1 | |a Meng, Fanju |e investigator |4 oth | |
| 700 | 1 | |a Li, Fengwei |e investigator |4 oth | |
| 700 | 1 | |a Gan, Fudong |e investigator |4 oth | |
| 700 | 1 | |a Xu, Gang |e investigator |4 oth | |
| 700 | 1 | |a Sang, Gengsheng |e investigator |4 oth | |
| 700 | 1 | |a Ma, Genshan |e investigator |4 oth | |
| 700 | 1 | |a Zhang, Guixia |e investigator |4 oth | |
| 700 | 1 | |a Tao, Guizhou |e investigator |4 oth | |
| 700 | 1 | |a Li, Guo |e investigator |4 oth | |
| 700 | 1 | |a Chen, Guoduo |e investigator |4 oth | |
| 700 | 1 | |a Xin, Guoqin |e investigator |4 oth | |
| 700 | 1 | |a Li, Guoqing |e investigator |4 oth | |
| 700 | 1 | |a Fu, Guosheng |e investigator |4 oth | |
| 700 | 1 | |a Chen, Guoxiong |e investigator |4 oth | |
| 700 | 1 | |a Lin, Hailong |e investigator |4 oth | |
| 700 | 1 | |a Guo, Haiping |e investigator |4 oth | |
| 700 | 1 | |a Lin, Haiyun |e investigator |4 oth | |
| 700 | 1 | |a Jiang, Hong |e investigator |4 oth | |
| 700 | 1 | |a Liu, Hong |e investigator |4 oth | |
| 700 | 1 | |a Luan, Hong |e investigator |4 oth | |
| 700 | 1 | |a Zhang, Hong |e investigator |4 oth | |
| 700 | 1 | |a Deng, Honghua |e investigator |4 oth | |
| 700 | 1 | |a Li, Hongwei |e investigator |4 oth | |
| 700 | 1 | |a Wang, Honhju |e investigator |4 oth | |
| 700 | 1 | |a Liu, Hualing |e investigator |4 oth | |
| 700 | 1 | |a Dong, Hui |e investigator |4 oth | |
| 700 | 1 | |a Liu, Hui |e investigator |4 oth | |
| 700 | 1 | |a Zhang, Huifang |e investigator |4 oth | |
| 700 | 1 | |a Wang, Huifeng |e investigator |4 oth | |
| 700 | 1 | |a Chu, Huimin |e investigator |4 oth | |
| 700 | 1 | |a Xi, Jiabin |e investigator |4 oth | |
| 700 | 1 | |a Yang, Jian |e investigator |4 oth | |
| 700 | 1 | |a Ye, Jianfeng |e investigator |4 oth | |
| 700 | 1 | |a Li, Jianhao |e investigator |4 oth | |
| 700 | 1 | |a Tao, Jianhong |e investigator |4 oth | |
| 700 | 1 | |a Liu, Jianwen |e investigator |4 oth | |
| 700 | 1 | |a Yang, JiaoMei |e investigator |4 oth | |
| 700 | 1 | |a Ding, Jiawang |e investigator |4 oth | |
| 700 | 1 | |a Tong, Jiayi |e investigator |4 oth | |
| 700 | 1 | |a Chen, Jie |e investigator |4 oth | |
| 700 | 1 | |a Jiang, Jie |e investigator |4 oth | |
| 700 | 1 | |a Yang, Jie |e investigator |4 oth | |
| 700 | 1 | |a Li, Jifu |e investigator |4 oth | |
| 700 | 1 | |a Yan, Jinchuan |e investigator |4 oth | |
| 700 | 1 | |a Hu, Jing |e investigator |4 oth | |
| 700 | 1 | |a Xu, Jing |e investigator |4 oth | |
| 700 | 1 | |a Wang, Jingfeng |e investigator |4 oth | |
| 700 | 1 | |a Diao, Jinglan |e investigator |4 oth | |
| 700 | 1 | |a Zhao, Jingshan |e investigator |4 oth | |
| 700 | 1 | |a Wei, Jinru |e investigator |4 oth | |
| 700 | 1 | |a Yi, Jinxing |e investigator |4 oth | |
| 700 | 1 | |a Su, Jinzi |e investigator |4 oth | |
| 700 | 1 | |a Tang, Jiong |e investigator |4 oth | |
| 700 | 1 | |a Chen, Jiyan |e investigator |4 oth | |
| 700 | 1 | |a Yin, Jiyan |e investigator |4 oth | |
| 700 | 1 | |a Fan, Juexin |e investigator |4 oth | |
| 700 | 1 | |a Guan, Jun |e investigator |4 oth | |
| 700 | 1 | |a Ge, Junbo |e investigator |4 oth | |
| 700 | 1 | |a Liu, Junming |e investigator |4 oth | |
| 700 | 1 | |a Deng, Junping |e investigator |4 oth | |
| 700 | 1 | |a Fang, Junping |e investigator |4 oth | |
| 700 | 1 | |a Li, Junxia |e investigator |4 oth | |
| 700 | 1 | |a Chen, Kaihong |e investigator |4 oth | |
| 700 | 1 | |a Luo, Kalan |e investigator |4 oth | |
| 700 | 1 | |a Wu, Keng |e investigator |4 oth | |
| 700 | 1 | |a Ji, Lang |e investigator |4 oth | |
| 700 | 1 | |a Li, Lang |e investigator |4 oth | |
| 700 | 1 | |a Jiang, Li |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Cardiovascular drugs and therapy |d 1988 |g 38(2024), 2 vom: 04. März, Seite 315-325 |w (DE-627)NLM012606367 |x 1573-7241 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2024 |g number:2 |g day:04 |g month:03 |g pages:315-325 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10557-022-07398-w |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2024 |e 2 |b 04 |c 03 |h 315-325 | ||